Portfolio company
Aptadir Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops RNA inhibitor-based therapeutics that reactivate silenced genes to treat patients with intractable cancers and rare genetic conditions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.
Arrakis Therapeutics
This biopharmaceutical company develops oral, small-molecule medicines that target RNA to treat patients with cancer, cardiovascular conditions, neurodegeneration and rare genetic diseases.
Aptatargets
The company develops aptamer-based therapeutic drugs for patients with acute ischemic stroke and other inflammatory or cardiovascular diseases.
Armatus
The company develops vectorized RNAi therapeutics to treat genetic neurological and neuromuscular diseases for patients with rare conditions.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Tacit Therapeutics
This company develops RNA trans-splicing medicines to repair genetic mutations for patients with inherited neurological diseases and other complex gene-mediated conditions.
ADARx Pharmaceuticals
This clinical-stage biotechnology company develops RNA-targeting therapeutics for patients with genetic, cardiometabolic, complement-mediated, and central nervous system diseases.